Morgan Stanley Boosts Sight Sciences (NASDAQ:SGHT) Price Target to $11.00

Sight Sciences (NASDAQ:SGHTGet Rating) had its price objective increased by Morgan Stanley from $10.00 to $11.00 in a report published on Friday morning, MarketBeat.com reports. They currently have an overweight rating on the stock.

A number of other equities research analysts have also weighed in on SGHT. Piper Sandler cut their price objective on Sight Sciences from $17.00 to $15.00 and set an overweight rating on the stock in a research report on Friday, August 12th. Bank of America started coverage on Sight Sciences in a research report on Tuesday, October 11th. They issued a neutral rating on the stock. Stifel Nicolaus reiterated an initiates rating on shares of Sight Sciences in a research report on Tuesday, July 26th. Citigroup dropped their price target on Sight Sciences from $13.00 to $9.00 in a research report on Wednesday, October 5th. Finally, Needham & Company LLC initiated coverage on Sight Sciences in a research report on Tuesday, October 4th. They set a hold rating on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Sight Sciences presently has a consensus rating of Moderate Buy and an average price target of $11.25.

Sight Sciences Price Performance

Shares of Sight Sciences stock opened at $11.28 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.73 and a quick ratio of 16.38. The business’s 50 day simple moving average is $7.06 and its two-hundred day simple moving average is $8.19. The stock has a market capitalization of $539.48 million, a P/E ratio of -6.30 and a beta of 1.21. Sight Sciences has a one year low of $5.35 and a one year high of $24.59.

Sight Sciences (NASDAQ:SGHTGet Rating) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.04). The business had revenue of $17.23 million during the quarter, compared to the consensus estimate of $16.22 million. Sight Sciences had a negative return on equity of 40.24% and a negative net margin of 130.24%. Analysts forecast that Sight Sciences will post -1.89 EPS for the current year.

Institutional Investors Weigh In On Sight Sciences

Several hedge funds have recently added to or reduced their stakes in SGHT. New York State Common Retirement Fund boosted its holdings in Sight Sciences by 146.5% in the first quarter. New York State Common Retirement Fund now owns 17,497 shares of the company’s stock worth $202,000 after acquiring an additional 10,400 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Sight Sciences in the first quarter worth $391,000. Swiss National Bank boosted its holdings in Sight Sciences by 7.3% in the first quarter. Swiss National Bank now owns 28,000 shares of the company’s stock worth $324,000 after acquiring an additional 1,900 shares in the last quarter. CNA Financial Corp boosted its holdings in Sight Sciences by 16.8% in the first quarter. CNA Financial Corp now owns 16,383 shares of the company’s stock worth $189,000 after acquiring an additional 2,356 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Sight Sciences by 84.8% in the first quarter. Bank of New York Mellon Corp now owns 54,512 shares of the company’s stock worth $630,000 after acquiring an additional 25,009 shares in the last quarter. 65.20% of the stock is owned by institutional investors.

About Sight Sciences

(Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

Read More

Analyst Recommendations for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.